DUXAP10 and neoplasm: An increasing number of oncology studies have reported that the overexpression of DUXAP10 in diverse tumor tissues (such as NSCLC (Wei et al., 2017), glioma (Wu et al., 2021), and ESCC (Wang et al., 2018)) could be used to distinguish normal from tumor tissues, making it highly promising for the early diagnosis of tumors.